BioWorld

Jan. 7, 2002

Abgenix Drops ABX-IL8 For RA Following Phase II Trial Results

Abgenix Inc. s stock took a small hit Friday following the disclosure that a Phase IIa study of its rheumatoid arthritis candidate failed to meet its endpoints. Read More

Aurora, Allergan Expand Work To Include GPCR Screening

Industry, Academia Knock Out Immune Rejection Gene From Porcine Xenotransplant Grafts

Acadia Partners With Amgen To Discover Small-Molecule Drugs

Other News To Note

3-D Pharma, J&J Collaborate On Small-Molecule Drug Discovery

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 25, 2026.

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...